Advanced search
Publication Cover
OncoImmunology Volume 4, 2015 - Issue 3
Submit an article Journal homepage
968
Views
3
CrossRef citations to date
0
Altmetric
Author's View

CD4+ T cell plasticity engenders robust immunity in response to cytokine therapy

Megan E NellesOntario Cancer Institute; Princess Margaret Cancer Centre; University Health Network; Toronto, Ontario, Canada;Department of Medical Biophysics; University of Toronto; Toronto, Ontario, CanadaCorrespondence[email protected]
&
Christopher J PaigeOntario Cancer Institute; Princess Margaret Cancer Centre; University Health Network; Toronto, Ontario, Canada;Department of Medical Biophysics; University of Toronto; Toronto, Ontario, Canada;Department of Immunology; University of Toronto; Toronto, Ontario, Canada
Article: e994370 | Received 10 Nov 2014, Accepted 25 Nov 2014, Published online: 16 Mar 2015

References

  • Couzin-Frankel J. Cancer immunotherapy. Science 2013; 342:1432-33; PMID:24357284; http://dx.doi.org/10.1126/science.342.6165.1432
  • Nelles ME, Moreau JM, Furlonger CL, Berger A, Medin JA, Paige CJ. Murine splenic CD4⁺ T cells, induced by innate immune cell interactions and secreted factors, develop antileukemia cytotoxicity. Cancer Immunol Res 2014; 11:1113-24; http://dx.doi.org/10.1158/2326-6066.CIR-13-0208
  • Labbe A, Nelles ME, Walia J, Jia L, Furlonger C, Nonaka T, Medin JA, Paige CJ. IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. J Cell Mol Med 2009; 13:1962-76; PMID:18624776; http://dx.doi.org/10.1111/j.1582-4934.2008.00412.x
  • Mucida D, Husain MM, Muroi S, van Wijk F, Shinnakasu R, Naoe Y, Reis BS, Huang Y, Lambolez F, Docherty M et al. Transcriptional reprogramming of mature CD4⁺ helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes. Nat Immunol 2013; 14:281-9; PMID:23334788; http://dx.doi.org/10.1038/ni.2523
  • Reis BS, Rogoz A, Costa-Pinto FA, Taniuchi I, Mucida D. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4⁺ T cell immunity. Nat Immunol 2013; 14:271-80; PMID:23334789; http://dx.doi.org/10.1038/ni.2518
  • Hunn MK, Hermans IF. Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines. OncoImmunology 2013; 2:4; http://dx.doi.org/10.4161/onci.23789
  • Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4⁺ T cells against NY-ESO-1. N Engl J Med 2008; 358:2698-703; PMID:18565862; http://dx.doi.org/10.1056/NEJMoa0800251
  • Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD. Enhancement of tumor-reactive cytotoxic CD4⁺ T-cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 2013; 1:235-44; PMID:24396833; http://dx.doi.org/10.1158/2326-6066.CIR-13-0068
  • Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222:357-68; PMID:18364014; http://dx.doi.org/10.1111/j.1600-065X.2008.00604.x
  • Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine franulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci 1993; 90:3539-43; http://dx.doi.org/10.1073/pnas.90.8.3539

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.